This Article Full Text Full Text (PDF) All Versions of this Article: 114/25/2815    most recent CIRCULATIONAHA.106.658088v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, M.-J. Articles by Park, S.-J. Search for Related Content PubMed PubMed Citation Articles by Kim, M.-J. Articles by Park, S.-J. Related Collections Echocardiography

(Circulation. 2006;114:2815-2822.)
© 2006 American Heart Association, Inc.

Interventional Cardiology

Long-Term Outcomes of Significant Mitral Regurgitation After Percutaneous Mitral Valvuloplasty

Mi-Jeong Kim, MD; Jae-Kwan Song, MD; Jong-Min Song, MD; Duk-Hyun Kang, MD; Young-Hak Kim, MD; Cheol Whan Lee, MD; Myeong-Ki Hong, MD; Jae-Joong Kim, MD; Seong-Wook Park, MD; Seung-Jung Park, MD

From the Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Correspondence to Jae-Kwan Song, MD, Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 388–1 Poongnap-dong Songpa-ku, Seoul 138–736 South Korea. E-mail jksong{at}amc.seoul.kr

Received August 14, 2006; revision received September 28, 2006; accepted October 19, 2006.

Background— Mild commissural mitral regurgitation (MR) is associated with significantly higher restenosis-free survival after percutaneous mitral valvuloplasty (PMV), which suggests that different mechanisms of significant MR after PMV may have different clinical courses. We therefore analyzed long-term prognostic factors of significant MR after PMV.

Methods and Results— Echocardiographic and clinical follow-up data on 380 patients were analyzed (286 women, mean age 44±11 years) who underwent PMV with the Inoue balloon technique between 1995 and 2000. Significant MR developed in 47 patients (12.4%). The survival rate at 8 years was 96±3% and 98±10% in patients with and without significant MR, respectively (P=0.084). The most frequent mechanism was commissural MR, or MR that originated at the site of successful commissurotomy, which occurred in 27 of 47 patients (57%), whereas noncommissural MR occurred in 20 (43%) patients, 12 (26%) with subvalvular damage resulting in chordae rupture and flail motion and 8 (17%) with leaflet laceration. The 8-year event-free survival rate was significantly lower in patients with significant MR than in those without (47±8% versus 83±3%, P<0.001) and was significantly higher in patients with commissural versus noncommissural MR (63±11% versus 29±11%, P<0.001). Of the 47 patients with significant MR, who were followed up for 74±29 months, 19 patients (40%) underwent mitral valve replacement, and 28 patients (60%) received medical treatment only. Patients with commissural MR had a significantly lower rate of mitral valve replacement than patients with noncommissural MR (15% versus 70%, P<0.001). Multivariate analysis showed that atrial fibrillation (odds ratio, 7.4; 95% CI, 1.1 to 56.4; P=0.038), mean mitral gradient immediately after PMV (odds ratio, 1.5; 95% CI, 1.1 to 2.0; P=0.009), and the mechanism of MR (odds ratio, 16.7; 95% CI, 2.3 to 122.2; P=0.005) were independent factors associated with mitral valve replacement.

Conclusions— Clinical outcome of patients with significant MR after PMV varied according to MR mechanism and the adequacy of hemodynamic improvement, which is easily assessed by echocardiography immediately after PMV.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				J.-K. Song, J.-M. Song, D.-H. Kang, S.-C. Yun, D. W. Park, S. W. Lee, Y.-H. Kim, C. W. Lee, M.-K. Hong, J.-J. Kim, et al. Restenosis and adverse clinical events after successful percutaneous mitral valvuloplasty: immediate post-procedural mitral valve area as an important prognosticator Eur. Heart J., May 2, 2009; 30(10): 1254 - 1262. [Abstract] [Full Text] [PDF]

				M. Nobuyoshi, T. Arita, S.-i. Shirai, N. Hamasaki, H. Yokoi, M. Iwabuchi, H. Yasumoto, and H. Nosaka Percutaneous Balloon Mitral Valvuloplasty: A Review Circulation, March 3, 2009; 119(8): e211 - e219. [Full Text] [PDF]

				S. Tsiaras and A. Poppas Mitral valve disease in pregnancy: outcomes and management Obstet Med, March 1, 2009; 2(1): 6 - 10. [Abstract] [Full Text] [PDF]

				A. Vahanian, B. Iung, L. Piérard, R. Dion, and J. Pepper CHAPTER 21 Valvular Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				S. H. Rahimtoola The Year in Valvular Heart Disease. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 760 - 770. [Full Text] [PDF]